TMCnet News
NovaBone Receives Notice of Allowance for US PatentNovaBone Products, a leading biologics bone graft device company, announced that the US Patent and Trademark Office (USPTO) has issued notice of allowance for US patent application 20140017281 for its "novel ionically cross-linked materials and methods for production." A Notice of Allowance is issued after the USPTO makes a determination that claims in a patent application are deemed to represent patentable subject matter. The patent will publish on or before September 21, 2015. The primary claims of the patent are a method for preparing a collagen bioactive glass ionically cross-linked composite where the bioactive glass present is 80% or greater by weight. "This invention is important in two ways," said Greg Pomrink, Vice President of Research & Development at NovaBone Products, "First, it allows the elimination of hazardous compounds such as foraldehyde or glutaraldehyde which have been commonly used for cross-linking collagen. Additionally, this intellectual property establishes NovaBone as the only provider of bioactive glass/collagen bone grafting composites where the amount of bone healing glass exceeds 80%." Art Wotiz, CEO of NovaBone Products added, "Under Greg's leadership, NovaBone has been successful at adding collagen formulating, processing and manufacturing as a core competency of the company. Combining this expertise with our leading-edge capabilities with bioactive glass has resulted in several new product launches over the last few months with more new products in development." With the development of the cross-linked composite as announced here, NovaBone Products is well positioned to provide new collagen technologies for repair and regenerative healing for a variety of clinical applications. In total, NovaBone Products provides seven devices within the field of orthopedics and six for dental indications providing the medical community with unparalleled versatility and the widest range of choices in bioactive graft devices. NovaBone is a privately held company based in Florida, USA since 2002 and developed the first bioactive synthetic bone graft offered to the orthopaedic community.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006356/en/ |
